{"id":476178,"date":"2020-03-25T14:10:02","date_gmt":"2020-03-25T14:10:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476178"},"modified":"2020-03-25T14:10:02","modified_gmt":"2020-03-25T14:10:02","slug":"fragile-x-syndrome-pipeline-upcoming-products-that-shall-drive-the-fxs-market-forward","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fragile-x-syndrome-pipeline-upcoming-products-that-shall-drive-the-fxs-market-forward_476178.html","title":{"rendered":"Fragile X Syndrome Pipeline: Upcoming products that shall drive the FXS market forward"},"content":{"rendered":"
\"Fragile<\/a><\/p>\n
\n
Fragile X Syndrome Pipeline<\/p><\/div>\n<\/div>\n<\/div>\n
Fragile X Syndrome pipeline report covers all the FXS pipeline products, key pharma companies, with individual share, patents details, details the pre-clinical developmental phase to the marketed phase, with a detailed description of the drug, mechanism of action, clinical studies, NDA approvals, collaborations, mergers and licensing opportunities in Fragile X Syndrome market. <\/div>\n

Fragile X syndrome (FXS) is a rare genetic disorder caused due to the mutations in the Fragile X mental retardation 1 (FMR1) gene. Also known as Martin-Bell syndrome, the disease occurs due to the absence of a protein – Fragile X mental retardation protein (FMRP) – required for normal development of the body.<\/p>\n

DelveInsight’s “Fragile X Syndrome Pipeline Insight, 2020<\/a>” report provides an in-depth view of present clinical development trends and growth prospects in the Fragile X Syndrome market.<\/p>\n

The report covers the Fragile X Syndrome pipeline landscape including treatment guidelines, commercial assessment and clinical assessment. The report covers all the products from the pre-clinical developmental phase to the marketed phase, with a detailed description of the drug, mechanism of action, clinical studies, NDA approvals (if any), and product development activities.<\/p>\n

The Fragile X Syndrome pipeline report also sheds light on the novel technologies, Fragile X Syndrome collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Robust Fragile X Syndrome Pipeline<\/strong><\/p>\n

Fragile X syndrome pipeline products comprise of several therapies such as ZYN002<\/strong> (Zynerba Pharmaceuticals), STX209<\/strong> (Seaside Therapeutics), OV101<\/strong> (Ovid Therapeutics), Trofinetide<\/strong> (Neuren Pharmaceuticals), BPN14770<\/strong> (Tetra Discovery Partners), and Bryostatin<\/strong> (Neurotrope Bioscience) that shall positively impact the Fragile X syndrome market during the study period (2017-2030).<\/p>\n

Request for Sample Pages<\/a><\/p>\n

Report Highlights <\/strong><\/p>\n